Voice of Value
High Medical Value defined
High Medical Value
Innovative solutions that provide medically actionable information and insights leading to outcomes that change lives.
Click to continue
We deliver this through:
High medical value (HMV) assays
that provide critical, actionable insights to inform therapeutic decisions, foster improved patient outcomes, and/or reduce healthcare costs.
Scroll right to continue
Companion diagnostics (CDx) that help clinicians choose the best treatment options for each patient.
Tests that determine
if a patient may benefit
from additional testing
or immediate intervention.
HMV predictive assays represent access to a broad range of cancer therapies, by identifying whether a patient is eligible for - or more likely to respond to - a specific therapy. By enabling targeted treatment strategies, they deliver additional economic value to health care systems, payers and society.
HMV analytic assays reveal critical information, such as specific cancer types or changes in infections, that provide a definitive basis for confident clinical decisions about additional testing.
HMV predictive assays represent access to a broad range of cancer therapies, by identifying whether a patient is eligible for - or more likely to respond to - a specific therapy. By enabling targeted treatment strategies, they deliver additional economic value to
health care systems, payers and society.
of High Medical Value assays that are making a difference in patients’ lives now
learn more >
VENTANA HER2 Dual ISH
Probe Cocktail Assay enables the pathologist to:
1. Determine HER2 gene
status that helps identify breast and gastric cancer patients eligible for treatment with HER2-targeted personaized therapies
2. Produce timely results that are highly reproducible and highly concordant with FISH
Indicated as an aid in
the assessment of breast
cancer patients for HER2
targeted treatment, the
VENTANA HER2 Dual ISH image analysis algorithm automatically enumerates signals and provides a HER/Ch17 ratio.
The VENTANA PD-L1 portfolio enables the pathologist to:
1. Assess the degree and likelihood of potential patient benefit from corresponding
PD-1/PD-L1 immunotherapies (TECENTRIQ,® KEYTRUDA,® IMFINZI,®
2. Generate reliable results that
enable timely therapeutic choices using a single fully automated BenchMark instrument
The uPath PD-L1 (SP263) image analysis (CE-IVD) algorithm quickly calculates PD-L1 (SP263) tumor cell staining positivity for user-defined regions of interest (ROI) – so pathologists can diagnose non-small cell lung cancer with confidence.
CINtec® PLUS Cytology
enables the pathologist to:
1. Confidently identify the presence of transforming HPV infections using the combination of p16 and Ki-67 biomarkers
2. Triage abnormal cervical cancer screening results to identify women who would benefit most from colposcopy
(EPR17341) Assay enables
the pathologist to:
1. Identify wild-type and fusion
TRK protein expression in a
wide range of solid tumors
2. Provide clinicians with a
resource-efficient way to determine which patients will potentially benefit from NGS testing, so they can make informed decisions, sooner
Only Roche offers this unique comprehensive solution that delivers global leadership in:
Enabling timely, actionable insights with standardized, fully automated tests, digital support for pathologists, and responsive service
confidence through products that deliver high quality and highly reliable, reproducible results
With the largest menu of ready-to-use IHC assays, including CDx, and our strong innovation pipeline, we remain at the diagnostic forefront
of precision medicine
Optimized assay system
Automated for use on the largest global
installed base of IHC/ISH staining platforms
2,911 3,983 777 459 2,946
NAM EMEA JAPAN LATAM APAC
14.5 million HMV tests
from Roche Tissue Diagnostics provided
clear answers for oncology patients,
often helping to guide treatment
Rigorous development discipline
Average work hours dedicated
Individual patient cases reviewed
Tissue types tested
of pathology reads performed
The global leader in CDx
we partner with
*based on oncology sales
of the top
For clinicians and patients, HMV assays are invaluable
We focus on outcomes-driven
innovation because patients need more than products – they need powerful solutions that bring us closer to a cure.
HMV assays make better outcomes possible for
patients like Amanda and so many others
© 2022 Roche
VENTANA, CINTEC and UPATH are trademarks of Roche. All other trademarks are the property of their respective owners.
Read Amanda's story here >